"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.631.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- ANG-(1-8)Octapeptide
- Angiotensin-(1-8) Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Angiotensin II, Isoleucine(5)-
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- Isoleucine(5)-Angiotensin
- Isoleucyl(5)-Angiotensin II
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in this website by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 3 | 4 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 2 | 5 |
| 2004 | 3 | 2 | 5 |
| 2005 | 4 | 4 | 8 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 5 | 8 |
| 2008 | 3 | 2 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 2 | 4 |
| 2011 | 5 | 3 | 8 |
| 2012 | 5 | 4 | 9 |
| 2013 | 3 | 2 | 5 |
| 2014 | 5 | 2 | 7 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 4 | 8 |
| 2021 | 0 | 4 | 4 |
| 2022 | 2 | 2 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles.
-
Injectable, reversibly thermoresponsive captopril-laden hydrogel for the local treatment of sensory loss in diabetic neuropathy. Sci Rep. 2024 08 16; 14(1):18978.
-
Nanobody-Mediated Dualsteric Engagement of the Angiotensin Receptor Broadens Biased Ligand Pharmacology. Mol Pharmacol. 2024 Feb 15; 105(3):260-271.
-
Angiotensin 1-7 exerts antioxidant effects, suppresses Mammalian Target of Rapamycin (mTOR) signaling, and inhibits apoptosis in renal proximal tubular cells. Peptides. 2024 Feb; 172:171136.
-
Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. Mol Ther. 2022 11 02; 30(11):3462-3476.
-
Evaluation of the Addition of Angiotensin II in Patients With Shock After Cardiac Surgery at a Veterans Affairs Medical Center. Ann Pharmacother. 2023 02; 57(2):141-147.
-
Adipocyte-Derived Serum Amyloid A Promotes Angiotensin II-Induced Abdominal Aortic Aneurysms in Obese C57BL/6J Mice. Arterioscler Thromb Vasc Biol. 2022 05; 42(5):632-643.
-
Second Heart Field-Derived Cells Contribute to Angiotensin II-Mediated Ascending Aortopathies. Circulation. 2022 03 29; 145(13):987-1001.
-
AIM2 Inflammasome Activation Contributes to Aortic Dissection in a Sporadic Aortic Disease Mouse Model. J Surg Res. 2022 04; 272:105-116.
-
Commentary: Is angiotensin II a game changer for vasoplegia after cardiac surgery, or is the jury still out? J Thorac Cardiovasc Surg. 2022 04; 163(4):1415-1416.
-
MKL1 cooperates with p38MAPK to promote vascular senescence, inflammation, and abdominal aortic aneurysm. Redox Biol. 2021 05; 41:101903.